Clinical trials: Carcinoma, Breast
Breast Cancer
Breast Cancer Surveillance Consortium
The Breast Cancer Surveillance Consortium (BCSC) database contains data from 1994-2009 on breast cancer screening, quality, and outcomes, and its main goal is to advance breast cancer research.
- Trial name
- BCSC (NCT01831778)
- Where
- United States
- Volunteers
- 2,345,817 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Breast Cancer
Brain Mets - Capecitabine Plus Sunitinib and WBRT
The purpose of this study is to assess the efficacy and safety of concurrent whole brain radiotherapy (WBRT) and capecitabine followed by combination capecitabine and sunitinib in treating patients with CNS metastases from breast…
- Trial name
- NCT00570908
- Testing
- sunitinib, capecitabine, WBRT
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Baylor Breast Care Center
Breast Cancer, Bone Metastases
A Study for Dynamic Prediction Model of Breast Cancer Bone Metastases
The purpose of this study is to identify the risk factors of bone metastasis in breast cancer patients so as to develop a dynamic prediction model using real world clinical data.
- Trial name
- NCT06544668
- Testing
- Breast cancer patients with bone metastasis, Breast cancer patients without bone metastasis
- Where
- China
- Volunteers
- 3,500 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Effectiveness of Liquid Crystal Contact Thermography in Detecting Pathological Changes in Female Breasts
The study is designed to evaluate the effectiveness of liquid crystal contact thermography in detecting pathological changes in female breasts compared to standard diagnostic methods.
- Trial name
- NCT03735550
- Testing
- Contact thermographic breast examination device
- Where
- 24 sites in Poland
- Volunteers
- 3,000 people
- Sponsor
- Jagiellonian University
Radiotherapy Side Effect, Locoregional Recurrence
RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients
This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each…
- Trial name
- Breastcancer (NCT04550910)
- Testing
- Hypofractionation Schedules for Breast Cancer patients after mastecomy
- Where
- Egypt
- Volunteers
- 166 people
- Sponsor
- National Cancer Institute, Egypt
Breast Cancer Awareness
Effectiveness of a Video and Mobile App in Breast Cancer Screening Awareness
Introduction: Breast cancer is the most common type of cancer in women in the worldandinTurkey. It also ranks first in cancer-related deaths in women.
- Trial name
- Application (NCT07059897)
- Testing
- Animation video and mobile phone application
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Özlem BEKDEMİR AK
Breast Neoplasms
Prediction of Axillary Lymph Node Metastasis Status in Breast Cancer Based on PET/CT Radiomics
Patients with suspected breast cancer undergoing PET/CT at our hospital. The PET/CT center's chief physician and senior attending physician reviewed the films together and disagreement, if any, was resolved by consensus.
- Trial name
- NCT05826197
- Testing
- Radiomics
- Volunteers
- 100 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Breast Cancer
Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer
The early diagnosis and evaluation of breast cancer is of great significance to its treatment and prognosis. Among the multiple factors affecting the prognosis, the degree of axillary lymph node metastasis is one of the most…
- Trial name
- NCT05346510
- Testing
- ALND Group
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shengjing Hospital
Metastatic Breast Cancer, HER2-negative Breast Cancer
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
This will be a single arm, open label pilot to test the combination of dapagliflozin, a commercially available SGLT-2 inhibitor, in combination with alpelisib + fulvestrant in patients with HR+/HER2- mBC.
- Trial name
- NCT05025735
- Testing
- Dapagliflozin 10Mg Tab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Saint Luke's Health System
HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
The goal of this Phase 1/2a interventional study is to evaluate the safety and tolerability of CRG-150 in relapsed/refractory HR+HER2- breast cancer, Triple Negative Breast Cancer (TNBC) and prostate cancer.
- Conditions
- HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer
- Trial name
- NCT07730125
- Testing
- CRG-150
- Volunteers
- 67 people
- Sponsor
- CoRegen, Inc.
Breast Cancer
The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
Breast cancer is a heterogeneous disease and can be classified into several distinctive subgroups. Triple-negative breast cancer(TNBC) is defined by lack of estrogen(ER), progesterone(PR) immunoreactivity and lack of human…
- Trial name
- NCT01732276
- Testing
- gefitinib
- Volunteers
- 50 people
- Sponsor
- Jiangmen Central Hospital
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy (CIPN)
Chinese Medicinal Component Relieves CIPN and Mitochondria Function
A randomized controlled trial was designed and conducted to confirm whether oral administration of the herb Moutan Cortex, which contains paeonol, can alleviate peripheral neuropathy in paclitaxel-treated cancer patients.
- Trial name
- NCT07693374
- Testing
- Moutan cortex
- Where
- Taiwan
- Sponsor
- Taiwan Municipal An-Nan Hospital-China Medical University
Osseous Lesions From Metastatic Breast Cancer
Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer
The purpose of this study is to examine for changes in the bone scan after treating with zoledronic acid (Zometa™). This study is designed to show if intravenous (IV) bisphosphonates, which are infused by vein, such as…
- Trial name
- NCT00582920
- Testing
- Zometa™
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer
Through the investigators' Breast Care Center at the University of Michigan Comprehensive Cancer Center, the investigators treat approximately 75 patients per year with neoadjuvant chemotherapy.
- Trial name
- NCT02455882
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan
Ductal Carcinoma In Situ
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
Primary Objectives: To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS) To evaluate the effect of a single dose of Herceptin…
- Trial name
- NCT00496808
- Testing
- Herceptin (Trastuzumab)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms, Triple Negative Breast Neoplasms
Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer
Breast cancer is the most common cancer in women worldwide. Its molecular classification, based on hormone receptors (estrogen and progesterone), HER2 and Ki-67, defines subtypes with different prognoses and treatments.
- Conditions
- Breast Neoplasms, Triple Negative Breast Neoplasms, HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
- Trial name
- NCT07856225
- Testing
- CDK4/6 Inhibitors, Anti-HER2 Therapy, Standard Breast Cancer Treatment
- Where
- Colombia
- Volunteers
- 370 people
- Sponsor
- Fundación Santa Fe de Bogota
Breast Cancer
Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)
The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body…
- Trial name
- PETRA (NCT01805908)
- Testing
- 111In-Pertuzumab + SPECT-CT
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Untreated Early-stage or Locally Advanced Breast Cancer
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients
The study is being conducted to evaluate the preliminary efficacy, safety, and pharmacokinetic characteristics of the combination of SHR-A1811 with Adebrelimab Injection in treatment-naive patients with early-stage or locally…
- Trial name
- NCT06592625
- Testing
- SHR-A1811, Adebrelimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Breast Cancer
Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
This study is designed to investigate the safety and efficacy of the combination of imatinib and vinorelbine in patients with advanced, anthracycline resistant breast cancer
- Trial name
- INV181 (NCT00372476)
- Testing
- Imatinib and Vinorelbine
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel, epirubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398489
- Testing
- trastuzumab, anastrozole, cyclophosphamide
- Where
- 5 sites in Germany
- Volunteers
- 94 people
- Sponsor
- Technical University of Munich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.